Global Spirometer Market

Spirometer Market Size, Share, Growth Analysis, By Product(Devices, Hand Held, Table Top, Desktop), By Technology(Volume Measurement, Flow Measurement, and Peak Flow Measurement), By End-use(Hospitals and Clinics, and Home Healthcare), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2503 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 92 | Figures: 76

Spirometer Market News

  • In April 2024, Clario acquired ArtiQ, a technology company. This acquisition strengthens Clario's Respiratory Solutions portfolio by integrating advanced artificial intelligence (AI) capabilities. It enhances Clario's capacity to innovate and deploy AI across its service offerings, aiming to advance the efficiency and effectiveness of clinical trials. 
  • In October 2023, Med Company and Sananet collaborated to revolutionize lung function tests. They integrated the Spirobank Smart Spirometer into the MedCor4U App, enabling patients at OLVG and HagaZiekenhuis to share FEV1, FVC, and flow-volume curve data with SananetOnline and SanaCoach Asthma. This collaboration allows patients to conduct lung function tests from home, with results immediately visible on both platforms for patients and healthcare providers. 
  • In September 2023, Alveofit announced that its innovative alveoair spirometer has received clearance from the US FDA for distribution in the United States. Alveofit specializes in digital therapeutics for respiratory care and aims to provide cost-effective and interoperable solutions for lung health. The alveoair spirometer offers real-time insights to healthcare providers, facilitating prompt interventions and enhancing respiratory care management.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Spirometer Market size was valued at USD 951.0 million in 2022 and is poised to grow from USD 1036.3 million in 2023 to USD 1989.1 million by 2031, growing at a CAGR of 8.52% in the forecast period (2024-2031). 

The market is competitive and driven by technological factors and the expansion strategies implemented in the markets. Businesses are concerned with the improvement of spirometry tools to increase precision, ease of use, and patient tolerance. New entrants are gradually increasing their presence with niche products and partnerships. This category of strategies entails forming partnerships, mergers, and acquisitions to enhance market position and leverage the increasing demand for respiratory diagnostic solutions in the global market. 'Baxter International Inc (US)  ', 'Midmark Corporation (US) ', 'FutureMed (US) ', 'COSMED SRL (Italy) ', 'MGC Diagnostics Corporation (US) ', 'Medical International Research (MIR) (Italy) ', 'Vyaire Medical Inc (US) ', 'Vitalograph (UK) ', 'NDD Medical Technologies Inc (Switzerland) ', 'Schiller AG (Switzerland) ', 'Jones Medical Instrument Company (US) ', 'Sibelmed (Spain) ', 'Medline Industries LP (US) ', 'NCE Empowering Safety (US) ', 'Teleflex Inc (US) ', 'The Contec Group (China) ', 'Medikro (Finland) ', 'SDI Diagnostics (US) ', 'Chest M.I., Inc (Japan) ', 'Fukuda Sangyo Co. Ltd., (Japan)'

The spirometers are demanding for early detection, disease management, and treatment intervention for people with respiratory disorders. In 2020, the COPD incidence was estimated 10.6% in both males and females, equivalent to 480 million cases. The estimates of COPD prevalence suggest that the figure of COPD patients will increase by 112 million by 2050, totaling 592 million or 9.3% from year 2020 to year 2050. This rising is mainly due to the increasing prevalence of COPD among female patients and LMICs. In females, COPD is expected to rise to 7.8% in 2020 to 8.3% in 2050. The number of the population aged 65 and over was 8% in 2020 and 8.3% in 2050, a relative increase of 6.4%. The global prevalence of COPD in females is projected to rise from 177 million in the year 2020 to 260 million by the year 2050, this a rise of 83 million, 47.1% relative increase. 

Advancements in spirometry technology: The development of new spirometry devices is now experiencing fast-growing demand in the global market due to better usability, portability, and cheaper prices. Some of the advancements include portable devices that have greatly enhanced respiratory care through enhanced portability and convenience of the devices to both the carers and the patients. These portable equipments allow pulmonary function tests in non-hospital environments, particularly in point-of-care and telemedicine settings. For instance, in January 2024, the Air Next spirometer developed by NuvoAir is a breakthrough, as it is the first spirometer approved by the FDA for home use. Moreover, incorporation with Smartphones has emerged as a trend that utilizes the existing popular devices to improve usability. spirometers are integrated with smartphone applications, which track patients’ respiratory health and share the data with their healthcare providers for assessment and management without physically visiting the clinic. 

North America held the largest market share in 2023 with 38.04% due to increasing incidences of respiratory diseases. Asthma and COPD incidence has led to higher spirometer sales because of disease necessity and acceptance among hospital doctors. Also, the United States has been at the forefront of embracing technologies to reduce the incidences of COPD. Such factors indicate that the market has good potential for growth in the future for the given forecast period. Chronic respiratory diseases are prevalent in the United States, which increases the need to monitor the conditions through portable handheld spirometers. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Spirometer Market

Report ID: SQMIG35A2503